FREM3: A Drug Target / Disease Biomarker (G166752)

Target Name: FREM3

NCBI ID: G166752

FREM3

Other Name(s): FREM3_HUMAN | FRAS1-related extracellular matrix protein 3 | FRAS1 related extracellular matrix 3 | OTTHUMP00000220417

FREM3: A Drug Target / Disease Biomarker

FREM3, a protein that is expressed in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for the treatment of future diseases.

FREM3 is a protein that is expressed in the brain and is involved in the formation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the blood and helps to protect it from harmful substances. However, this barrier is also responsible for limiting the delivery of many important drugs to the brain, making it difficult to treat certain neurological and psychiatric disorders.

One of the challenges in treating neurological and psychiatric disorders is the difficulty of reaching the affected area of the brain. Because the brain is surrounded by the blood-brain barrier, it is difficult to deliver drugs directly to the source of the problem. This can make it difficult to effectively treat conditions such as Alzheimer's disease, Parkinson's disease, and other neurological disorders.

FREM3 has been identified as a potential drug target because of its unique structure and function. Its structure is similar to that of other proteins that are involved in the formation of the blood-brain barrier, and it has been shown to be involved in the regulation of brain function. This makes it an attractive target for drugs that can help to improve blood-brain barrier function and increase the delivery of drugs to the brain.

In addition to its potential as a drug target, FREM3 has also been identified as a potential biomarker for neurological and psychiatric disorders. Its expression has been shown to be affected in a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other disorders. This makes it an attractive target for drugs that can help to reduce the expression of FREM3 in these conditions.

FREM3's potential as a drug target and biomarker has significant implications for the treatment of neurological and psychiatric disorders. Its unique structure and function make it an attractive target for drugs that can help to improve blood-brain barrier function and reduce the expression of FREM3 in these conditions. Further research is needed to fully understand its potential and to develop effective treatments.

Protein Name: FRAS1 Related Extracellular Matrix 3

Functions: Extracellular matrix protein which may play a role in cell adhesion

The "FREM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FREM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets